Tragacanth gum
Based on 1 Customer Validation
Tragacanth gum is an orally active anionic composite polysaccharide and multifunctional biomaterial. Tragacanth gum exhibits biocompatibility, mucoadhesion and renoprotective effects, and effectively promotes wound closure and tissue healing. Tragacanth gum can be isolated from Astragalus gummifer. Tragacanth gum acts as an emulsifier and drug delivery carrier, and is also widely used in fields such as 3D scaffolds, tissue engineering and green nanoparticle preparation. High doses of Tragacanth gum may induce reversible forestomach squamous epithelial hyperplasia in mice, but show no mutagenic or carcinogenic activity. Tragacanth gum is commonly used in studies related to diseases including systemic candidiasis, rheumatoid arthritis and osteosarcoma.
For research use only. We do not sell to patients.
- CAS No.: 9000-65-1
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Iron-crosslinked deesterified Tragacanth gum gel microspheres support the adhesion of L929 fibroblasts and show no toxicity to HeLa, HepG2 and L929 cell lines[1].
Calcium alginate composite microspheres containing Tragacanth gum (25-50% w/w) enhance the viability, proliferation, osteogenic differentiation level, and expression of angiogenic markers of MG-63 osteoblasts compared with calcium alginate microspheres[1].
GPTMS-conjugated Tragacanth gum composite scaffolds support the proliferation and differentiation of MG-63 osteoblasts[1].
Bacterial cellulose/keratin electrospun nanofibers containing Tragacanth gum enhance the adhesion and proliferation capacities of L929 fibroblasts[2].
Calcium alginate microspheres containing Tragacanth gum (25-50 (w/v)) enhance the viability, proliferation and differentiation of encapsulated MG-63 osteocytes, and upregulate HIF-1α expression to strengthen pro-angiogenic activity[2].
Collagen hydrogels containing Tragacanth gum (25 mg/mL; 7-21 d) promote osteogenic differentiation of human adipose-derived mesenchymal stem cells by increasing ALP activity, calcium deposition, and the expression of osteogenesis-related genes[2].
Poly (vinyl alcohol)/tragacanth gum/Polycaprolactone hybrid nanofiber scaffolds support the growth and proliferation of NIH 3T3 fibroblasts[2].
Tragacanth gum exhibits antibacterial activity against Escherichia coli and Staphylococcus aureus, and shows no significant toxicity to human fibroblasts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human adipose-derived mesenchymal stem cells (h-ASCs)
-
Concentration:25 mg/mL
-
Incubation Time:7, 14, 21 days
-
Result:Showed no cytotoxicity to h-ASCs.
Increased alkaline phosphatase (ALP) activity significantly at 7, 14, and 21 days compared to controls.
Increased calcium content and deposition significantly at 7, 14, and 21 days compared to controls.
Up-regulated expression of osteogenic-related genes (Runx2, collagen type 1, osteonectin, osteocalcin) significantly at 7, 14, and 21 days compared to controls.
In Vivo
Oral AmpB-loaded TG-AA hydrogels effectively treat systemic candidiasis in male albino mice with no observed liver or kidney toxicity[1].
Topical tragacanth gum application (topical; single treatment period) achieves 90% closure of full-thickness dorsal wounds in male rats after 7 days[1].
Tragacanth gum (2:1 PCL/GT mass ratio, with 3% curcumin loading; implantation directly onto the wound site) enhances full-thickness diabetic skin wound healing in rats, improving wound closure and histological regenerative markers[2].
Tragacanth gum (0.625-5.0% dietary concentration; dietary; ad libitum daily; 13 weeks) causes only slight, biologically unimportant plasma GGT elevations and dose-related, male-specific, nonneoplastic squamous-cell hyperplasia of the forestomach, with no other meaningful toxic effects when administered orally to B6C3F1 mice for 13 weeks[3].
Tragacanth gum (5.0% dietary concentration; dietary; ad libitum daily; up to 48 weeks) induces only transient, reversible squamous-cell hyperplasia of the forestomach with no meaningful toxic or proliferative effects, and its overall oral toxicity is negligible when administered orally to male B6C3F1 mice for up to 48 weeks[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rabbit[1]
-
Dosage:5 mg/kg
-
Administration:p.o.; single dose
-
Result:Achieved a maximum plasma concentration of 271.47 ng/mL (vs.
114.87 ng/mL for free AmpB solution).
Extended circulation time to reach peak concentration (4 hours vs.
2 hours for free drug).
-
Animal Model:Diabetic rats[2]
-
Dosage:2:1 PCL/GT mass ratio, with 3% curcumin loading
-
Administration:implantation directly onto the wound site
-
Result:Enhanced wound closure observed at 5, 10, and 15 days post-surgery compared to untreated controls.
Improved granulation tissue formation, epithelial regeneration, angiogenesis, and collagen deposition in treated wounds.
Chemical Information
-
CAS No. 9000-65-1
-
Appearance Solid
-
Color White to light yellow
-
SMILES
[Tragacanth gum]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
H2O : ≥ 20 mg/mL
* "≥" means soluble, but saturation unknown.
Protocols
-
3D Hydrogel Synthetic Scaffold Culture
3D hydrogel synthetic scaffold culture embeds cells, spheroids, organoids, or tissue fragments inside a hydrated crosslinked polymer network so that cells receive matrix and cell-cell cues in three dimensions rather than from a flat plastic surface. A literature-supported model protocol is PEG-4MAL hydrogel culture, in which four-arm maleimide-terminated PEG is functionalized with cysteine-containing adhesive peptides such as RGD and crosslinked with protease-degradable peptides such as GPQ-W; this creates a defined, modular scaffold that supports human organoid generation and culture. The readouts are scaffold-supported growth, morphology, lumen formation, budding, viability, proliferation, lineage-marker expression, and matrix-dependent expansion or differentiation; reported assays include transmitted-light imaging, immunofluorescence, in situ hybridization, qRT-PCR, and rheological characterization.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nazemi Z, et al. A review on tragacanth gum: A promising natural polysaccharide in drug delivery and cell therapy. Int J Biol Macromol. 2023;241:124343. [Content Brief]
[2]. Taghavizadeh Yazdi ME, et al. Gum Tragacanth (GT): A Versatile Biocompatible Material beyond Borders. Molecules. 2021;26(6):1510. Published 2021 Mar 10. [Content Brief]
[3]. Hagiwara A, et al. Oral toxicity study of tragacanth gum in B6C3F1 mice: development of squamous-cell hyperplasia in the forestomach and its reversibility. J Toxicol Environ Health. 1991;34(2):207-218. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)